Skip to main content
Bavarian Nordic logo

Bavarian Nordic — Investor Relations & Filings

Ticker · BAVA ISIN · DK0015998017 LEI · 2138006JCDVYIN6INP51 CO Manufacturing
Open in API
Filings indexed 2,297 across all filing types
Latest filing 2025-03-31 Regulatory Filings
Country DK Denmark
Listing CO BAVA

About Bavarian Nordic

https://www.bavarian-nordic.com/

Bavarian Nordic is a fully integrated biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. The company's portfolio targets infectious diseases, including vaccines for Mpox, rabies, and typhoid. It is a leading global provider of travel vaccines and serves as a key partner for governments and international organizations in addressing public health preparedness needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is titled "Company Announcement" and details the U.S. FDA approval of a freeze-dried formulation of JYNNEOS® vaccine. It provides key highlights, context about government contracts (BARDA), and safety information. This format—a concise, immediate release of significant, time-sensitive corporate news (a major regulatory approval)—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a full annual report (10-K), a detailed quarterly report (IR), a transcript (CT), or a presentation (IP), and it is a direct announcement of a major event rather than just announcing the publication of a report (RPA), the most fitting category is Earnings Release (ER), as these announcements often contain the most critical, summarized financial or operational news. Given the nature of the news (FDA approval), it could also be considered a Regulatory Filing (RNS), but ER is often used for major operational milestones that impact future performance. Since it is a major operational/regulatory milestone announcement, ER is the best fit among the primary reporting categories, though RNS is a strong secondary possibility if ER is reserved strictly for financial results.
2025-03-31 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a press release dated March 31, 2025, announcing that the FDA has approved the freeze-dried version of the JYNNEOS® vaccine. It details the approval, the background of the contract with the US government (BARDA), and includes standard sections like 'Important Safety Information' and 'Forward-Looking Statements'. This format is characteristic of an official announcement of a significant corporate event, specifically related to product approval and regulatory milestones. It is not a comprehensive annual report (10-K), an interim report (IR), or a transcript (CT). Since it is an announcement of a major regulatory event and provides key financial/operational context, it fits best as an Earnings Release (ER) if it were tied to quarterly results, but since it is a standalone regulatory/product update, and given the options, it most closely resembles a general announcement that might accompany earnings or be a standalone press release. However, the content is a detailed announcement of a regulatory achievement (FDA approval) and associated contract details, which often accompanies or is categorized similarly to an Earnings Release (ER) in terms of market impact, or sometimes as a Regulatory Filing (RNS) if it were less detailed. Given the depth of the announcement regarding the product and government contracts, it is a significant corporate disclosure. Since it is not a formal financial statement or a transcript, and it is a detailed announcement, 'ER' (Earnings Release) is often used broadly for major operational/regulatory news releases, but 'RNS' (Regulatory Filings) is the best fit for a non-financial, specific regulatory milestone announcement that doesn't fit other specific categories like DIV or CAP. However, looking closely at the definitions, this is a major corporate news announcement. If it were purely a regulatory filing notification, RNS would fit. If it were a summary of financial results, ER would fit. Since it is a detailed announcement of a major product approval, it functions as a key piece of information for investors. In many databases, major product news like this is often classified under the general 'Regulatory Filings' (RNS) or sometimes grouped with 'Earnings Release' (ER) if it's the primary news of the day. Given the specific nature of the FDA approval, RNS is the most appropriate fallback for a specific regulatory event announcement that isn't a standard financial report. The document ends with a 'Selskabsmeddelelse nr. 12 / 2025' (Company Announcement No. 12 / 2025), which strongly suggests a general regulatory/corporate announcement, making RNS the most suitable category.
2025-03-31 Danish
Director's Dealing 2025
Director's Dealing Classification · 99% confidence The document is titled 'Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer' (Reporting of transactions in shares and related securities by persons discharging managerial responsibilities and persons closely associated with them). It details specific transactions (purchases/transfers of RSUs and grants of RSUs) made by senior management (CEO, CFO, CCO, COO) on March 5, 2025. This content directly corresponds to the reporting requirements for insider trading or director's dealings, which falls under the 'Director's Dealing' category. This is explicitly covered by the definition for Director's Dealing (Code: DIRS): 'Report of personal share transactions by company directors and executives (insider trades)'. The reference to EU Regulation No 596/2014 further confirms this regulatory context. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K), as it focuses solely on insider transactions, not overall financial performance.
2025-03-05 Danish
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document is titled "Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer" (Notification of transactions in shares and related securities of Bavarian Nordic by persons discharging managerial responsibilities and persons closely associated with them). It explicitly references EU Regulation No 596/2014 and details transactions (purchase/vesting/grant of RSUs) made by senior management (CEO, CFO). This content directly corresponds to the definition of Director's Dealing (insider trades) reports. The corresponding code is DIRS.
2025-03-05 Danish
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities' and details acquisitions and grants of shares/RSUs by executives (Paul Chaplin, Henrik Juuel, etc.) on March 5, 2025. This content directly corresponds to insider trading reports or director's dealings, which are mandated disclosures for executive transactions. The filing category 'Director's Dealing (Code: DIRS)' is the most appropriate fit for reporting personal share transactions by company directors and executives.
2025-03-05 English
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document is titled "Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such." It explicitly references compliance with Article 19 of Regulation No. 596/2014 on Market Abuse, which mandates the disclosure of insider transactions by management personnel. The content details the 'Acquisition of shares' (vesting of RSUs) and 'Grant' of Restricted Stock Units by executives like the President and CEO and the CFO. This perfectly matches the definition of Director's Dealing (insider trades by executives).
2025-03-05 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.